
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

**FORM S-8
REGISTRATION STATEMENT
UNDER THE SECURITIES ACT OF 1933**

BRIDGEBIO PHARMA, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation or organization)

84-1850815
(I.R.S. Employer Identification No.)

3160 Porter Drive, Suite 250
Palo Alto, CA
(Address of Principal Executive Offices)

94304
(Zip Code)

2021 AMENDED AND RESTATED BRIDGEBIO PHARMA, INC. STOCK OPTION AND INCENTIVE PLAN
(Full title of the plan)

Brian C. Stephenson
Chief Financial Officer
BridgeBio Pharma, Inc.
3160 Porter Drive, Suite 250
Palo Alto, CA 94304
(Name and address of agent for service)

(650) 391-9740
(Telephone number, including area code, of agent for service)

Copies to:

Mitchell S. Bloom, Esq.
Maggie L. Wong, Esq.
Natalie T. Martirossian, Esq.
Goodwin Procter LLP
3 Embarcadero Center, 28th Floor
San Francisco, CA 94111
Telephone: (415) 733-6000

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definition of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer
Non-accelerated filer

Accelerated filer
Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act.

**REGISTRATION OF ADDITIONAL SHARES
PURSUANT TO GENERAL INSTRUCTION E**

Pursuant to General Instruction E of Form S-8, BridgeBio Pharma, Inc. is filing this Registration Statement on Form S-8 (the "Registration Statement") with the Securities and Exchange Commission (the "Commission") to register 7,531,278 additional shares of its common stock under the 2021 Amended and Restated BridgeBio Pharma, Inc. Stock Option and Incentive Plan (formerly known as the Amended and Restated BridgeBio Pharma, Inc. 2019 Stock Option and Incentive Plan) (the "2021 Plan"), pursuant to the provisions of the 2021 Plan providing for an automatic increase in the number of shares of common stock reserved and available for issuance under the 2021 Plan on January 1, 2023. In accordance with the instructional note to Part I of Form S-8 as promulgated by the Commission, the information specified by Part I of the Form S-8 has been omitted from this Registration Statement. The contents of the Registrant's Registration Statements on Form S-8 (File Nos. [333-232491](#), [333-236872](#), [333-239718](#), [333-252394](#) and [333-263009](#)), filed with the Commission on July 1, 2019, March 4, 2020, July 7, 2020, January 25, 2021 and February 25, 2022, respectively, are hereby incorporated by reference pursuant to General Instruction E.

PART II

INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

Item 8. Exhibits.

See the Exhibit Index below for a list of exhibits filed as part of this registration statement on Form S-8, which Exhibit Index is incorporated herein by reference.

EXHIBIT INDEX

Exhibit No.	Description
4.1	Form of Amended and Restated Certificate of Incorporation of the Registrant (1)
4.2	Form of Amended and Restated Bylaws of the Registrant (2)
4.3	Specimen Common Stock Certificate (3)
5.1*	Opinion of Goodwin Procter LLP
23.1*	Consent of Independent Registered Public Accounting Firm to BridgeBio Pharma, Inc.
23.2*	Consent of Goodwin Procter LLP (included in Exhibit 5.1)
24.1*	Power of Attorney (included on signature page)
99.1	2021 Amended and Restated Stock Option and Incentive Plan and Forms thereunder (4)
107*	Filing Fee Table

* Filed herewith.

- (1) Filed as Exhibit 3.1 to the Registrant's Current Report on Form 8-K, filed on July 3, 2019 and incorporated herein by reference.
- (2) Filed as Exhibit 3.2 to the Registrant's Registration Statement on Form S-4, filed on November 6, 2020 and incorporated herein by reference.
- (3) Filed as Exhibit 4.1 to the Registrant's Amendment No. 3 to Registration Statement on Form S-1, filed on June 24, 2019 and incorporated herein by reference.
- (4) Filed as Exhibit 10.1 to the Registrant's Annual Report on Form 10-K, filed on February 25, 2022 and incorporated herein by reference.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Palo Alto, State of California, this 6th day of February, 2023.

BRIDGEBIO PHARMA, INC.

By: /s/ Neil Kumar

Neil Kumar, Ph.D.

Chief Executive Officer

POWER OF ATTORNEY AND SIGNATURES

KNOW ALL BY THESE PRESENT, that each individual whose signature appears below hereby constitutes and appoints each of Neil Kumar and Brian C. Stephenson as such person's true and lawful attorney-in-fact and agent with full power of substitution and resubstitution, for such person in such person's name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement on Form S-8, and to file the same, with all exhibits thereto, and all documents in connection therewith, with the Securities and Exchange Commission granting unto each said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as such person might or could do in person, hereby ratifying and confirming all that any said attorney-in-fact and agent, or any substitute or substitutes of any of them, may lawfully do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the date indicated below.

Signature	Title	Date
<u>/s/ Neil Kumar</u> Neil Kumar, Ph.D.	Chief Executive Officer and Director <i>(Principal Executive Officer)</i>	February 6, 2023
<u>/s/ Brian C. Stephenson</u> Brian C. Stephenson, Ph.D., CFA	Chief Financial Officer <i>(Principal Financial Officer and Principal Accounting Officer)</i>	February 6, 2023
<u>/s/ Eric Aguiar</u> Eric Aguiar, M.D.	Director	February 6, 2023
<u>/s/ Jennifer E. Cook</u> Jennifer E. Cook	Director	February 6, 2023
<u>/s/ Douglas A. Dachille</u> Douglas A. Dachille	Director	February 6, 2023
<u>/s/ Ronald J. Daniels</u> Ronald J. Daniels	Director	February 6, 2023
<u>/s/ Andrea Ellis</u> Andrea Ellis	Director	February 6, 2023

<u>/s/ Fred Hassan</u> Fred Hassan	Director	February 6, 2023
<u>/s/ Charles Homcy</u> Charles Homcy, M.D.	Director	February 6, 2023
<u>/s/ Andrew W. Lo</u> Andrew W. Lo, Ph.D.	Director	February 6, 2023
<u>/s/ James C. Momtazee</u> James C. Momtazee	Director	February 6, 2023
<u>/s/ Ali Satvat</u> Ali Satvat	Director	February 6, 2023
<u>/s/ Brenton L. Saunders</u> Brenton L. Saunders	Director	February 6, 2023
<u>/s/ Richard H. Scheller</u> Richard H. Scheller, Ph.D.	Director	February 6, 2023
<u>/s/ Randal Scott</u> Randal Scott, Ph.D.	Director	February 6, 2023
<u>/s/ Hannah A. Valantine</u> Hannah A. Valantine, M.D.	Director	February 6, 2023



Goodwin Procter LLP
Three Embarcadero Center
San Francisco, CA 94111

goodwinlaw.com
+1 415 733 6000

February 6, 2023

BridgeBio Pharma, Inc.
3160 Porter Drive, Suite 250
Palo Alto, CA 94304

Re: Securities Being Registered under Registration Statement on Form S-8

We have acted as counsel to you in connection with your filing of a Registration Statement on Form S-8 (the "Registration Statement") pursuant to the Securities Act of 1933, as amended (the "Securities Act"), on or about the date hereof relating to an aggregate of 7,531,278 shares (the "Shares") of common stock, \$0.001 par value per share ("Common Stock"), of BridgeBio Pharma, Inc., a Delaware corporation (the "Company"), that may be issued pursuant to the Company's 2021 Amended and Restated Stock Option and Incentive Plan (formerly known as the Amended and Restated BridgeBio Pharma, Inc. 2019 Stock Option and Incentive Plan) (the "2021 Plan").

We have reviewed such documents and made such examination of law as we have deemed appropriate to give the opinions set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company.

The opinion set forth below is limited to the Delaware General Corporation Law.

For purposes of the opinion set forth below, we have assumed that no event occurs that causes the number of authorized shares of Common Stock available for issuance by the Company to be less than the number of then unissued Shares.

Based on the foregoing, we are of the opinion that the Shares have been duly authorized and, upon issuance and delivery against payment therefor in accordance with the terms of the 2021 Plan, will be validly issued, fully paid and nonassessable.

This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in *74 Business Lawyer* 815 (Summer 2019).

We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Registration Statement. In giving our consent, we do not admit that we are in the category of persons whose consent is required under Section 7 of the Securities Act or the rules and regulations thereunder.

Very truly yours,

/s/ Goodwin Procter LLP

GOODWIN PROCTER LLP

CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM

We consent to the incorporation by reference in this Registration Statement on Form S-8 of our reports dated February 24, 2022, relating to the financial statements of BridgeBio Pharma, Inc. and the effectiveness of BridgeBio Pharma, Inc.'s internal control over financial reporting, appearing in the Annual Report on Form 10-K of BridgeBio Pharma, Inc. for the year ended December 31, 2021.

/s/ Deloitte & Touche LLP

San Francisco, California
February 6, 2023

CALCULATION OF REGISTRATION FEE

Form S-8
(Form Type)

BridgeBio Pharma, Inc.
(Exact name of Registrant as Specified in its Charter)

Newly Registered Securities

Security Type	Security Class Title	Fee Calculation Rule	Amount Registered(1)	Proposed Maximum Offering Price Per Share(2)	Maximum Aggregate Offering Price	Fee Rate	Amount of Registration Fee
Equity	Common Stock, \$0.001 par value per share, 2021 Amended and Restated Stock Option and Incentive Plan	Rule 457(c) and Rule 457(h)	7,531,278 (3)	\$9.19	\$69,212,444.82	\$0.00011020	\$7,627.21
Total Offering Amounts					\$69,212,444.82		—
Total Fees Previously Paid							—
Total Fee Offsets							—
Net Fee Due							\$7,627.21

- (1) Pursuant to Rule 416 under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of common stock which become issuable under the above-named plans by reason of any stock dividend, stock split, recapitalization or any other similar transaction effected without the receipt of consideration which results in an increase in the number of our outstanding shares of common stock.
- (2) Estimated solely for the purpose of calculating the registration fee pursuant to Rule 457 of the Securities Act, and based on the average of the high and low sales prices of the registrant’s common stock, as quoted on the Nasdaq Global Select Market on January 31, 2023.
- (3) Represents 7,531,278 additional shares of common stock that were automatically added to the shares authorized for issuance under the 2021 Amended and Restated Stock Option and Incentive Plan (the “2021 Plan”) on January 1, 2023, pursuant to an “evergreen” provision contained in the 2021 Plan. Pursuant to the provision contained in the 2021 Plan, on January 1, 2022 and each January 1 thereafter, the number of shares authorized for issuance under the 2021 Plan is automatically increased by 5% of the outstanding number of shares of common stock on the immediately preceding December 31 or such lesser amount of shares as determined by the administrator of the 2021 Plan.